Skin antisepsis with chlorhexidine

PreclinicalSmall molecule

Skin antisepsis with chlorhexidine is one of 6 small molecule programs targeting Total Joint Arthroplasty. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Total Joint ArthroplastyActive, not recruiting

Total Joint ArthroplastyPreclinical

Active, not recruiting

Competition

Competitive Landscape

7 competitors in Total Joint Arthroplasty

#DrugCompanyPhaseTrials

Cyklokapron

JJ Molner

Approved

3 2

Benadryl

PParkedale

Approved

1 3

Xarelto

Bayer Aspirin

1 5

Liposomal Bupivacaine

TTLC Biopharmaceuticals, Inc.

Preclinical

1 6

Skin antisepsis with chlorhexidine

NNorthwell Health

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Total Joint Arthroplasty1 trial

Chlorhexidine Versus Betadine in Preventing Colonization of Femoral Nerve Catheters After Total Joint Arthroplasty (TJA)

Withdrawn·NNorthwell Health·N/A·NCT00896402

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Skin antisepsis with chlorhexidine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Skin antisepsis with chlorhexidine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Skin antisepsis with chlorhexidine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Northwell Health company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: NNorthwell Health

Skin antisepsis with chlorhexidine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Total Joint Arthroplasty1 trial

References

Drug Info

Quick Facts

Related News